CDT

CDT Equity Inc

0.8840

Nov 09 • 3:13 PM ET -0.4260 (-32.52%)

Healthcare Biotechnology USA Nano NASD

Today, 10:03 AMNon-binding $2 Corvus bid 8-K drops CDT 23% after Friday reverse-split rally

Peers: BDRX MTVA ORMP PCSA FBIO TLSA XTLB RZLT ERNA SCNI

Index	-
Market Cap	0.90M
Enterprise Value	1.40M
Income	-37.10M
Sales	-
Book/sh	4084.02
Cash/sh	0.69
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	4
IPO	Mar 28, 2022

P/E	0.00
Forward P/E	-
PEG	-
P/S	-
P/B	0.00
P/C	1.29
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	0.00
Current Ratio	0.10
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	No / No

EPS (ttm)	1816250.00
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	61.18% -
Sales past 3/5Y	- -
EPS Y/Y TTM	98.24%
Sales Y/Y TTM	-
EPS Q/Q	-
Sales Q/Q	-
Earnings	-
EPS/Sales Surpr.	- -

Insider Own	90.50%
Insider Trans	0.00%
Inst Own	9.50%
Inst Trans	-
ROA	-55.20%
ROE	-69.70%
ROIC	-
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-66.33%
SMA50	-99.06%
SMA200	-100.00%
Trades

Shs Outstand	1.02M
Shs Float	0.02M
Short Float	30.80%
Short Ratio	0.01
Short Interest	0.01M
52W High	355000.00 -100.00%
52W Low	0.78 13.33%
Volatility	28.35% 24.55%
ATR (14)	10.01
RSI (14)	15.02
Beta	1.60
Rel Volume	4.57
Avg Volume	769.46K
Volume	3,117,220

Perf Week	-36.86%
Perf Month	-93.84%
Perf Quarter	-99.94%
Perf Half Y	-99.99%
Perf YTD	-100.00%
Perf Year	-100.00%
Perf 3Y	-100.00%
Perf 5Y	-
Perf 10Y	-
Recom	-
Target Price	-
Prev Close	1.31
Price	0.88
Change %	-32.52%

Oct-30-26 08:32AM	CDT Equity Welcomes U.S. Regulatory Development Supporting Expanded Access to Compounded Peptides (GlobeNewswire) -11.69%
Oct-27-26 08:00AM	CDT Partners with Manoira to Explore Enhancing Animal Health Products Ahead of Launch (GlobeNewswire) -14.89%
Oct-14-26 08:10AM	CDT Highlights Sarborg's Solid-Form Patent Filing on a First-in-Class Respiratory Asset (GlobeNewswire) -46.67%
Sep-29-26 07:00AM	CDT Highlights Sarborg's Expanding Quantum Computing IP Portfolio and Application to Drug Discovery (GlobeNewswire) -23.68%
Sep-25-26 08:10AM	CDT Equity Inc. Announces Reverse Stock Split (GlobeNewswire) -33.88%
06:30AM	Loading…
Sep-18-26 06:30AM	CDT Partners with QIMA Life Sciences to Evaluate Novel Tapinarof Combinations in Psoriasis and Vitiligo (GlobeNewswire) -8.18%
Sep-10-26 07:00AM	CDT Highlights Sarborg's Application of Signature Intelligence and Quantum Computing Models to Mental Health (GlobeNewswire) -42.54%
Sep-02-26 05:00AM	CDT Provides Capital Update and Confirms No Nasdaq Deficiencies (GlobeNewswire) -38.51%
Sep-01-26 08:00AM	CDT Appoints Co-Founder James Bligh as Chief Executive Officer to Lead Next Phase of Growth (GlobeNewswire) -11.90%
Aug-28-26 05:00AM	CDT Validates Enhanced Solid-Form Properties Within Its IP Portfolio (GlobeNewswire) -10.11%
Aug-25-26 05:00AM	CDT Announces Investment in Pep'd, Expanding into the Fast-Growing US Peptide Market (GlobeNewswire) -17.67%
Aug-03-26 08:30AM	CDT Increases Stake in Sarborg following its Quantum Computing and Intellectual Property Expansion (GlobeNewswire)
Jul-20-26 08:30AM	CDT Highlights Sarborg's Patent Filing Extending Quantum-Enabled PRISM Platform to Sugarcane (GlobeNewswire) +13.75%
Jul-16-26 08:00AM	CDT Equity Inc. Announces Reverse Stock Split (GlobeNewswire)
Jun-26-26 08:30AM	CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development (GlobeNewswire) -10.81%
08:30AM	Loading…
Jun-18-26 08:30AM	CDT Notes Strategic Investment into Sarborg and Expansion into Quantum Computing (GlobeNewswire) +47.19%
Jun-16-26 08:30AM	CDT Equity Announces Debt Update and New Loan Facility (GlobeNewswire)
May-28-26 04:15PM	CDT Equity Inc. Announces Receipt of Nasdaq Deficiency Letter (GlobeNewswire) -13.63% +9.46%
May-27-26 08:00AM	CDT Announces Canadian Patent for AZD5904 in Male Infertility (GlobeNewswire) +24.39%
May-07-26 08:30AM	CDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis Market (GlobeNewswire) -7.96%
May-06-26 08:30AM	CDT Advances AZD5904 into Global Patent Phase and Initiates Partnering Discussions (GlobeNewswire) +8.65%
Apr-16-26 08:30AM	CDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven Discovery (GlobeNewswire) -24.41%
Apr-07-26 08:30AM	CDT Notes Sarborg Publication of PRISM Framework Expanding AI (GlobeNewswire) +6.84%
Mar-26-26 08:30AM	CDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent Filings (GlobeNewswire) -9.61%
Mar-25-26 08:00AM	CDT Equity Inc. Announces Reverse Stock Split (GlobeNewswire) -12.00%
Mar-23-26 08:30AM	CDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing Strategy (GlobeNewswire)
Mar-18-26 08:30AM	CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth (GlobeNewswire)
Mar-12-26 08:30AM	CDT Notes Sarborg Expansion into Rare Disease Signature Intelligence (GlobeNewswire)
Mar-05-26 08:30AM	CDT Equity Notes Sarborg Filing of U.S. Provisional Patent Application for AI Signature Agent (GlobeNewswire) -5.80%
Mar-04-26 08:30AM	CDT Positions for Transformational Growth (GlobeNewswire) +14.23%
08:30AM	Loading…
Feb-24-26 08:30AM	CDT Equity Notes Sarborg Expansion into Bacteria and Agrochemicals (GlobeNewswire)
Feb-20-26 08:30AM	CDT Acquires Strategic Stake in Sarborg to Transform its AI-Driven Asset Strategy (GlobeNewswire) -19.29%
Jan-02-26 08:30AM	CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy (GlobeNewswire) +12.50%
Oct-17-25 08:30AM	CDT Equity Increases Bitcoin Holding (GlobeNewswire)
Oct-09-25 08:00AM	CDT Equity Inc. Announces Reverse Stock Split (GlobeNewswire) -11.92%
Sep-17-25 08:30AM	CDT Executes Cryptocurrency Treasury Reserve Strategy (GlobeNewswire) +40.10%
Sep-03-25 08:30AM	CDT Board Authorizes Adoption of Cryptocurrency Treasury Reserve Strategy (GlobeNewswire) -9.77%
Aug-26-25 08:30AM	CDT Equity Identifies New Biological Target Validating AI-Driven Repurposing Strategy (GlobeNewswire) -10.42%
Aug-05-25 08:30AM	Conduit to Change Name to CDT Equity Inc. (GlobeNewswire)
Jul-08-25 08:30AM	Conduit Engages Consultant to Explore Cryptocurrency Reserve Strategy (GlobeNewswire)
Jul-07-25 08:30AM	Conduit Pharmaceuticals Files New Patents Following AI-Driven Combination Discoveries (GlobeNewswire) -17.12%
Jun-04-25 08:30AM	Conduit Pharmaceuticals Enters Joint Development Agreement with Manoira to Advance AZD1656 and AZD5658 in Animal Health (GlobeNewswire) -17.03%
May-22-25 08:30AM	Conduit Pharmaceuticals Inc. Listing on Nasdaq Capital Market (GlobeNewswire) -12.92%
May-21-25 08:30AM	Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance (GlobeNewswire) -17.91%
May-16-25 08:30AM	Conduit Pharmaceuticals Inc. Announces Reverse Stock Split (GlobeNewswire)
May-09-25 08:30AM	Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases (GlobeNewswire)
May-08-25 08:30AM	Conduit Pharmaceuticals Files Composition of Matter Patent for AZD5904 Creating Robust IP Foundation for Pipeline Asset (GlobeNewswire) -5.21%
Apr-16-25 08:30AM	Conduit Pharmaceuticals Announces Leadership Changes (GlobeNewswire) -12.97%
Apr-11-25 08:30AM	Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA (tapinarof) with Enhanced Therapeutic and Market Extension Prospects (GlobeNewswire) -14.94%
Apr-10-25 08:30AM	Conduit Pharmaceuticals Announces up to $1,000,000 Share Repurchase Program (GlobeNewswire) +72.58%
Apr-07-25 08:30AM	Conduit Pharmaceuticals Expands Partnership with Sarborg Limited to Leverage Machine Learning Data Analysis for Pipeline Optimization (GlobeNewswire)
Mar-31-25 08:30AM	Conduit Pharmaceuticals Receives U.S. Patent Approval For Its Lead Asset Targeting Autoimmune Diseases (GlobeNewswire) -12.25%
Mar-19-25 08:30AM	Conduit Pharmaceuticals Provides Research and Development Update on Progress for Pipeline Assets AZD1656, AZD5658, and AZD5904 (GlobeNewswire) -8.66%
Mar-07-25 04:53AM	Is Conduit Pharmaceuticals Inc. (CDT) the Best Micro Cap Stock to Buy Now? (Insider Monkey)
Mar-06-25 09:35AM	Conduit Pharmaceuticals Provides Update on Nasdaq Stock Market Hearing Panel (GlobeNewswire)
Feb-20-25 08:00AM	Conduit Progresses Phase II of its AI Initiative with Sarborg (GlobeNewswire)
Feb-13-25 08:00AM	Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus Erythematosus Model (GlobeNewswire) -8.43%
Feb-11-25 09:00AM	Conduit Pharmaceuticals Announces Debt Repayment and Partial Conversion of Senior Secured Note (GlobeNewswire)
Feb-08-25 06:08AM	Conduit Pharmaceuticals Inc. (CDT) Advances AI-Driven Drug Development to Phase II (Insider Monkey)
Feb-07-25 08:00AM	Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development (GlobeNewswire) +83.87%
Jan-28-25 05:30AM	Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug Development with Artificial Intelligence (GlobeNewswire) -6.97%
Jan-23-25 08:00AM	Conduit Pharmaceuticals Inc. Announces Reverse Stock Split (GlobeNewswire) -20.00%
Jan-22-25 08:00AM	Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline (GlobeNewswire) -7.41%
Dec-12-24 07:30AM	Conduit Pharmaceuticals to Revolutionize Drug Development Through Agreement to Use Artificial Intelligence and Cybernetics (GlobeNewswire) -7.13%
Nov-21-24 07:30AM	Conduit Pharmaceuticals Receives Further Patent Approval For Lead Asset Targeting Autoimmune Disorders (GlobeNewswire) +16.90%
Nov-19-24 04:30PM	Conduit Pharmaceuticals Announces Appointment of Simon Fry to Board of Directors (GlobeNewswire)
Nov-05-24 07:40AM	Conduit Pharmaceuticals announces new addition to autoimmune pipeline (TipRanks) +6.80%
Nov-04-24 07:30AM	Conduit Pharmaceuticals Announces New Addition to its Autoimmune Pipeline (GlobeNewswire) +11.80%
Nov-01-24 04:45PM	Conduit Pharmaceuticals Announces Debt Restructuring and Additional Notes (GlobeNewswire)
Aug-28-24 08:00AM	Conduit Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -5.54%
Aug-12-24 07:00AM	Conduit Pharmaceuticals Selects Initial Indications for Lead Clinical Candidate Targeting Autoimmune Disorders (GlobeNewswire) -10.53%
Aug-08-24 06:30AM	Conduit Pharmaceuticals Enters into Exclusive License Agreement with AstraZeneca for Multiple Assets to Advance Potential First-in-Class Treatments (GlobeNewswire)
Jul-16-24 02:52PM	Conduit Pharmaceuticals Granted Patent Approval For Autoimmune Diseases Treatment (Exec Edge)
08:12AM	Why Is Conduit Pharmaceuticals (CDT) Stock Up 73% Today? (InvestorPlace)
07:43AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
07:30AM	Conduit Pharmaceuticals Receives Patent Approval For Its Lead Asset Targeting Autoimmune Diseases (GlobeNewswire)
Jun-13-24 08:00AM	Conduit Pharmaceuticals to Join Russell 3000 Index (GlobeNewswire) -6.05%
May-29-24 04:21PM	A Presidio Property Trust Major Investment To Be Part of Russell 2000 (GlobeNewswire)
May-15-24 09:53AM	CDT Stock Earnings: Conduit Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
Mar-19-24 10:57AM	Conduit Pharmaceuticals Adds Key Leadership Positions (Exec Edge)
07:00AM	Conduit Pharmaceuticals Appoints Dr. Joanne Holland as Chief Scientific Officer (GlobeNewswire)
Mar-11-24 02:26PM	Conduit Pharmaceuticals Opens New Laboratory in UK (Exec Edge) +32.37%
07:00AM	Conduit Pharmaceuticals Announces Opening of Prime Laboratory Space in Europe's Leading Life Sciences Hub (GlobeNewswire)
Jan-31-24 08:30AM	Conduit Pharmaceuticals to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire) -7.42%
Nov-02-23 08:30AM	Conduit Pharmaceuticals to Participate in the 14th Annual Jefferies London Healthcare Conference (GlobeNewswire)
Oct-30-23 08:39AM	Why Is Conduit Pharmaceuticals (CDT) Stock Up 66% Today? (InvestorPlace) +49.52%
Oct-11-23 08:30AM	Conduit Pharmaceuticals Partners with ClinConnect on Cocrystal Development Program for AZD1656 (GlobeNewswire) -12.00%
Oct-06-23 09:29AM	Conduit Pharma CEO Tapolczay on Biopharma Differentiation, Pipeline (Exec Edge) -13.83%
08:30AM	Presidio Property Trust Announces Closing of Merger of Its Sponsored SPAC Murphy Canyon Acquisition Corp Now Trading as Conduit Pharmaceuticals (Nasdaq: CDT and CDTTW) (GlobeNewswire)
Sep-22-23 09:01AM	Conduit Pharmaceuticals and Murphy Canyon Acquisition Corp. Announce Completion of Business Combination (GlobeNewswire)
Sep-20-23 05:40PM	Murphy Canyon Acquisition Corp. Announces Stockholder Approval of the Proposed Combination with Conduit Pharmaceuticals Limited (ACCESSWIRE) -8.94% +32.32%
Sep-13-23 08:30AM	Presidio Property Trust, Inc. Announces Establishment of a Special Committee of the Board and Exploration of Strategic Alternatives (GlobeNewswire)
Sep-07-23 04:30PM	Murphy Canyon Acquisition Corp. Announces Postponement of Its Special Meeting of Stockholders for Approving Its Initial Business Combination With Conduit (ACCESSWIRE)
Aug-31-23 04:05PM	Murphy Canyon Acquisition Corp. Announces Postponement of its Special Meeting of Stockholders for Approving its Initial Business Combination with Conduit (ACCESSWIRE)
Aug-16-23 08:30AM	SEC Declares Form S-4 Registration Statement "Effective" for Proposed Business Combination of Murphy Canyon Acquisition Corp. with Conduit Pharmaceuticals Limited (ACCESSWIRE)

Show Previous News

CDT Equity Inc., a data-driven biopharmaceutical company, focuses on identifying, enhancing, and monetising therapeutic assets. The company's pipeline includes AZD1656, a glucokinase activator that is in Phase II trials for the treatment of autoimmune disorders, including uveitis, Hashimoto's thyroiditis, preterm labor, and renal transplant; AZD5658, which is in Phase I clinical trial for the treatment of Type 2 Diabetes Mellitus; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It also provides treatments for inflammatory disorders, oncology, dermatology, rare diseases and animal health. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.

Co-FounderMr. James Bligh

Chief Scientific OfficerDr. Joanne M. Holland

Head of Strategy & LicensingDr. David Joszef Tapolczay

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CDT

CDT Equity Inc

Upgrade your Finviz experience